From TG3 Leonardo to national media: press recognition supports Hemera’s path toward the clinical phase
Following the recent publication in the prestigious international journal Immunity by Cell Press of data related to the REMaST® cell therapy, Hemera is pleased to announce the significant media coverage received from leading Italian print and broadcast outlets.
The research, which demonstrates the possibility of “educating” macrophages to transform them from inactive cells into powerful allies in nervous system regeneration, has generated broad media attention. The in-depth feature aired by TG3 Leonardo highlighted the scientific relevance of the discovery, describing it as a new hope for the treatment of spinal cord injuries.
The news rapidly reached major national news agencies and newspapers. Outlets such as ANSA, Il Sole 24 Ore (Radiocor), La Stampa, and Quotidiano Sanità analyzed the impact of the discovery, emphasizing Hemera’s role as a leading player within the Italian biotech ecosystem. Media engagement will continue in the coming weeks, with further in-depth coverage expected on Focus and TG4.
“The attention received from national media represents recognition of the long-standing research efforts of our team and confirms the scientific and social value of our mission,” commented Hemera’s CEO. “As we approach the publication of the full print issue of Immunity on February 10, our focus remains on advancing toward the clinical phase, with the goal of translating this scientific breakthrough into a tangible therapeutic solution for patients.”
To ensure maximum transparency and accessibility, Hemera has compiled a comprehensive media dossier collecting the main press coverage to date. The dossier is available for download and will be continuously updated as new media contributions are published.